Abstract
Background and Objectives. For purposes of therapeutic decision making, we used quantitative polymerase chain reaction (PCR) for molecular follow-up of 55 patients with chronic myeloid leukemia (CML) in complete remission (CR) after allogeneic bone marrow transplantation (BMT) from HLA compatible donors. Design and Methods. A total of 402 bone marrow samples from 40 patients transplanted in chronic phase (group 1) and 15 in accelerated/blastic phase (group 2) were analyzed by qualitative and quantitative PCR. Results. Regarding clinical outcome, 34/40 (85%) group 1 vs. 8/15 (54%) group 2 patients are alive. Only 1/40 (2.5%) group 1 patient relapsed, as against 6/15 (40%) in group 2 (p = 0.0002). At qualitative PCR, 8/40 (19%) group 1 vs. 9/15 (60%) group 2 patients were positive, with a significantly greater total number of positive samples in group 2 (33/129, 27% vs. 16/273, 5%; p1 year after BMT was significantly lower in group 1 patients (4/40 patients, 10% vs. 9/15 patients, 60%; p = 0.01). At quantitative PCR, 4/8 (50%) group 1 patients were positive only once (<400 transcripts/μg RNA). In group 2, 9/15 (60%) patients had 3 or more positive samples (always with >4,000 coples/mg RNA); therapeutic interventions (cyclosporin A discontinuation, temporary α-Interferon or donor lymphocyte infusion) restored molecular remission in 4/9 (44%) cases. Interpretation and Conclusions. This study indicates that quantitative PCR could provide practical indications capable of directing therapeutic interventions for transplanted CML patients, especially those transplanted in accelerated/blastic phase, for whom intensive monitoring is required. (C) 2000, Ferrata Storti Foundation.
| Original language | English |
|---|---|
| Pages (from-to) | 653-658 |
| Number of pages | 6 |
| Journal | Haematologica |
| Volume | 85 |
| Issue number | 6 |
| Publication status | Published - Jun 2000 |
Fingerprint
Keywords
- Chronic myelogenous leukemia
- DLI
- Minimal residual disease
- Q-PCR
ASJC Scopus subject areas
- Hematology
Cite this
Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation. / Martinelli, Giovanni; Montefusco, Vittorio; Testoni, Nicoletta; Amabile, Marilina; Saglio, Giuseppe; Ottaviani, Emanuela; Terragna, Carolina; Bonifazi, Francesca; Rosti, Gianantonio; Bandini, Giuseppe; Tura, Sante.
In: Haematologica, Vol. 85, No. 6, 06.2000, p. 653-658.Research output: Contribution to journal › Article
}
TY - JOUR
T1 - Clinical value of quantitative long-term assessment of bcr-abl chimeric transcript in chronic myelogenous leukemia patients after allogeneic bone marrow transplantation
AU - Martinelli, Giovanni
AU - Montefusco, Vittorio
AU - Testoni, Nicoletta
AU - Amabile, Marilina
AU - Saglio, Giuseppe
AU - Ottaviani, Emanuela
AU - Terragna, Carolina
AU - Bonifazi, Francesca
AU - Rosti, Gianantonio
AU - Bandini, Giuseppe
AU - Tura, Sante
PY - 2000/6
Y1 - 2000/6
N2 - Background and Objectives. For purposes of therapeutic decision making, we used quantitative polymerase chain reaction (PCR) for molecular follow-up of 55 patients with chronic myeloid leukemia (CML) in complete remission (CR) after allogeneic bone marrow transplantation (BMT) from HLA compatible donors. Design and Methods. A total of 402 bone marrow samples from 40 patients transplanted in chronic phase (group 1) and 15 in accelerated/blastic phase (group 2) were analyzed by qualitative and quantitative PCR. Results. Regarding clinical outcome, 34/40 (85%) group 1 vs. 8/15 (54%) group 2 patients are alive. Only 1/40 (2.5%) group 1 patient relapsed, as against 6/15 (40%) in group 2 (p = 0.0002). At qualitative PCR, 8/40 (19%) group 1 vs. 9/15 (60%) group 2 patients were positive, with a significantly greater total number of positive samples in group 2 (33/129, 27% vs. 16/273, 5%; p1 year after BMT was significantly lower in group 1 patients (4/40 patients, 10% vs. 9/15 patients, 60%; p = 0.01). At quantitative PCR, 4/8 (50%) group 1 patients were positive only once (<400 transcripts/μg RNA). In group 2, 9/15 (60%) patients had 3 or more positive samples (always with >4,000 coples/mg RNA); therapeutic interventions (cyclosporin A discontinuation, temporary α-Interferon or donor lymphocyte infusion) restored molecular remission in 4/9 (44%) cases. Interpretation and Conclusions. This study indicates that quantitative PCR could provide practical indications capable of directing therapeutic interventions for transplanted CML patients, especially those transplanted in accelerated/blastic phase, for whom intensive monitoring is required. (C) 2000, Ferrata Storti Foundation.
AB - Background and Objectives. For purposes of therapeutic decision making, we used quantitative polymerase chain reaction (PCR) for molecular follow-up of 55 patients with chronic myeloid leukemia (CML) in complete remission (CR) after allogeneic bone marrow transplantation (BMT) from HLA compatible donors. Design and Methods. A total of 402 bone marrow samples from 40 patients transplanted in chronic phase (group 1) and 15 in accelerated/blastic phase (group 2) were analyzed by qualitative and quantitative PCR. Results. Regarding clinical outcome, 34/40 (85%) group 1 vs. 8/15 (54%) group 2 patients are alive. Only 1/40 (2.5%) group 1 patient relapsed, as against 6/15 (40%) in group 2 (p = 0.0002). At qualitative PCR, 8/40 (19%) group 1 vs. 9/15 (60%) group 2 patients were positive, with a significantly greater total number of positive samples in group 2 (33/129, 27% vs. 16/273, 5%; p1 year after BMT was significantly lower in group 1 patients (4/40 patients, 10% vs. 9/15 patients, 60%; p = 0.01). At quantitative PCR, 4/8 (50%) group 1 patients were positive only once (<400 transcripts/μg RNA). In group 2, 9/15 (60%) patients had 3 or more positive samples (always with >4,000 coples/mg RNA); therapeutic interventions (cyclosporin A discontinuation, temporary α-Interferon or donor lymphocyte infusion) restored molecular remission in 4/9 (44%) cases. Interpretation and Conclusions. This study indicates that quantitative PCR could provide practical indications capable of directing therapeutic interventions for transplanted CML patients, especially those transplanted in accelerated/blastic phase, for whom intensive monitoring is required. (C) 2000, Ferrata Storti Foundation.
KW - Chronic myelogenous leukemia
KW - DLI
KW - Minimal residual disease
KW - Q-PCR
UR - http://www.scopus.com/inward/record.url?scp=0033938844&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=0033938844&partnerID=8YFLogxK
M3 - Article
VL - 85
SP - 653
EP - 658
JO - Haematologica
JF - Haematologica
SN - 0390-6078
IS - 6
ER -